We are live on ! Find out more
Lazard Asset Management

Lazard Asset Management Portfolio holdings

AUM $60.8B
1-Year Est. Return 22.47%
This Fund
S&P 500
This Quarter Est. Return
+8.53%
1 Year Est. Return
+22.47%
3 Year Est. Return
+62.53%
5 Year Est. Return
+77.87%
10 Year Est. Return
+305.76%
AUM
$94B
AUM Growth
+$5.35B
Cap. Flow
-$10.2B
Cap. Flow %
-10.87%
Top 10 Hldgs %
22.25%
Holding
2,551
New
400
Increased
743
Reduced
692
Closed
262

Sector Composition

Rank Sector Weight
1 Technology 20.36%
2 Healthcare 14.2%
3 Financials 13.3%
4 Industrials 9.5%
5 Consumer Discretionary 9.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
LSCC icon
1176
Lattice Semiconductor
LSCC
$19.2B
$126K ﹤0.01%
1,642
+149
+10% +$11.1K
BCC icon
1177
Boise Cascade
BCC
$3.03B
$125K ﹤0.01%
1,760
+404
+30% +$26K
HWKN icon
1178
Hawkins
HWKN
$2.73B
$125K ﹤0.01%
3,183
+421
+15% +$15.6K
TGNA
1179
DELISTED
TEGNA Inc
TGNA
$125K ﹤0.01%
6,775
-93
-1% -$1.86K
WIRE
1180
DELISTED
Encore Wire Corp
WIRE
$125K ﹤0.01%
877
+264
+43% +$34.2K
ANAB icon
1181
AnaptysBio
ANAB
$1.65B
$124K ﹤0.01%
3,589
+1,347
+60% +$42.7K
CNDT icon
1182
Conduent
CNDT
$271M
$123K ﹤0.01%
+23,142
New +$138K
HYT icon
1183
BlackRock Corporate High Yield Fund
HYT
$1.37B
0
III icon
1184
Information Services Group
III
$241M
$123K ﹤0.01%
16,196
+2,228
+16% +$17.9K
SIVR icon
1185
abrdn Physical Silver Shares ETF
SIVR
$4.45B
$123K ﹤0.01%
5,500
ALNY icon
1186
Alnylam Pharmaceuticals
ALNY
$28.6B
$122K ﹤0.01%
723
-1,037
-59% -$193K
MCB icon
1187
Metropolitan Bank Holding Corp
MCB
$1.15B
$122K ﹤0.01%
1,154
-601
-34% -$57.1K
EGRX
1188
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$122K ﹤0.01%
2,405
+248
+11% +$12.8K
BHVN
1189
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$121K ﹤0.01%
879
-8,117
-90% -$1.03M
PARA
1190
DELISTED
Paramount Global Class B
PARA
$120K ﹤0.01%
4,000
-3,054
-43% -$105K
EAD
1191
Allspring Income Opportunities Fund
EAD
$377M
0
IWD icon
1192
iShares Russell 1000 Value ETF
IWD
$83.4B
$119K ﹤0.01%
711
+457
+180% +$74.9K
LQDT icon
1193
Liquidity Services
LQDT
$1.31B
$119K ﹤0.01%
5,399
+1,288
+31% +$28.7K
TDOC icon
1194
Teladoc Health
TDOC
$1.27B
$119K ﹤0.01%
1,304
-5,995
-82% -$717K
SMAR
1195
DELISTED
Smartsheet Inc.
SMAR
$119K ﹤0.01%
1,538
+35
+2% +$2.44K
MASI
1196
DELISTED
Masimo
MASI
$118K ﹤0.01%
404
-149
-27% -$42.4K
OFIX icon
1197
Orthofix Medical
OFIX
$413M
$118K ﹤0.01%
3,820
+339
+10% +$11.3K
UFPI icon
1198
UFP Industries
UFPI
$5.14B
$118K ﹤0.01%
1,288
+179
+16% +$15.1K
PRFT
1199
DELISTED
Perficient Inc
PRFT
$117K ﹤0.01%
906
-12,229
-93% -$1.61M
GRIN
1200
DELISTED
Grindrod Shipping Holdings Ltd. Ordinary Shares
GRIN
$117K ﹤0.01%
6,490
+1,987
+44% +$29.1K

Similar funds

Lazard Asset Management's Q4 2021 Portfolio in Review

As of Q4 2021, Lazard Asset Management held 2,551 positions worth $94B, up 6% from $88.6B the previous quarter. Its ten largest holdings account for 22% of the portfolio.

Lazard Asset Management withdrew a net $10.2B in Q4 2021, closing 262 positions and reducing 692 holdings. Its most notable exit was Innospec, an estimated $21M position sold in full.

By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 20% a quarter earlier, followed by Healthcare and Financials.

Against the trend, Lazard Asset Management opened a new position in Wells Fargo 7.5% Non Cumv Perp Conv worth $922K.

  • Lazard Asset Management's largest Q4 2021 buy was Wells Fargo 7.5% Non Cumv Perp Conv: 61,920 shares worth $922K.
  • Lazard Asset Management added most to Pinnacle West Capital in Q4 2021, an estimated $455M increase.
  • Lazard Asset Management's biggest Q4 2021 reduction was JPMorgan Chase, cutting an estimated $545M.
  • Lazard Asset Management fully exited Innospec in Q4 2021, selling an estimated $21M.
  • Lazard Asset Management's ten largest holdings make up 22% of its $94B portfolio in Q4 2021.
  • Lazard Asset Management opened 400 new positions and closed 262 in Q4 2021.
  • Lazard Asset Management's portfolio value rose 6% quarter-over-quarter to $94B.

Based on Lazard Asset Management's 13F filing for Q4 2021, filed 9 Feb 2022.